August holds 5 big FDA decisions; Spark weighs installment payments for blindness therapy;

> The FDA this month is expected to announce big approval decisions for companies including Bristol-Myers Squibb ($BMY), Alkermes ($ALKS) and Amgen ($AMGN). Report

> In Q2, Endo's ($ENDP) branded pharma revenue increased 27%, while generics posted a 24% top-line rise. Release

> Spark Therapeutics ($ONCE) is weighing installment payments for a gene therapy candidate for blindness that analysts predict will be pricey. Report

> Kwang Dong Pharma will market Orexigen's ($OREX) weight loss drug, Contrave, in South Korea. Report

> Shire ($SHPG) has launched the second annual Excellence in ADHD Patient Group Awards. Release

> People on extended-interval prophylaxis regimens with new, long-acting Biogen ($BIIB) hemophilia therapy Eloctate experienced low bleeding rates in a Phase III study. Release

> GlaxoSmithKline ($GSK) is rolling out a tooth sensitivity awareness campaign for Sensodyne toothpaste in India. Report

And Finally... A U.K. company is preparing to launch the first traditional Chinese medicine approved in the country. Report (sub. req.)

Suggested Articles

Amgen could soon face new competition in the PCSK9 class, but an efficacy boost in treating high-risk heart attack patients could help keep it ahead.

Having already whiffed on one crucial heart failure trial, Novartis is focusing on "profound" data from its Entresto studies in hopes for another go.

Bristol-Myers Squibb and Pfizer's Eliqus has taken the U.S. warfarin alternative market by storm, but can afib screening amp it up even more?